Differential metabolites between the model group and the EB-H treatment group were mainly involved in purine metabolism, cytochrome P450, caffeine metabolism, arginine and proline metabolism, the mTOR signalling pathway, insulin resistance, and glycerophospholipid metabolism (Figure 5D). The gene discussed is MTOR; the disease is Insulin resistance.